Rosen, Lee S.
LoRusso, Patricia
Ma, Wen Wee
Goldman, Jonathan W.
Weise, Amy
Colevas, A. Dimitrios
Adjei, Alex
Yazji, Salim
Shen, Angela
Johnston, Stuart
Hsieh, Hsin-Ju
Chan, Iris T.
Sikic, Branimir I.
Funding for this research was provided by:
Genentech
Genentech
Genentech
Article History
Received: 24 May 2016
Accepted: 3 July 2016
First Online: 16 July 2016
Compliance with ethical standards
:
: Lee S. Rosen, Patricia LoRusso, and Jonathan W. Goldman have received research funding from Genentech, Inc. Salim Yazji is a prior employee and current shareholder of Exelixis and is a current employee of Baxalta. Angela Shen is a prior employee of Exelixis and a current employee of Arvinas. Stuart Johnston is a shareholder and prior employee of Exelixis and a current employee of Nektar Therapeutics. Hsin-Ju Hsieh and Iris T. Chan are employees and shareholders of Roche. Branimir I. Sikic has received research funding from Exelixis, Genentech, Inc., Novartis, and Sanofi, and is a consultant for Novartis and Threshold Pharmaceuticals. Wen Wee Ma, Amy Weise, A. Dimitrios Colevas, and Alex Adjei declare that they have no potential conflicts of interest.
: All procedures performed involving human participants in the protocol were approved by Institutional Review Boards prior to patient recruitment and conducted in accordance International Conference on Harmonization E6 Guidelines for Good Clinical Practice.
: Informed consent was obtained from all individual participants included in the study.